ClinicalTrials.gg
RecruitingNCT01501838PH-HIBAUpdated Aug 24, 2025

Pulmonary Hypertension Institutional Registry at Hospital Italiano de Buenos Aires

An observational study in Hypertension, Pulmonary Arterial, sponsored by Hospital Italiano de Buenos Aires. Recruiting at 1 site in Argentina. Open to participants aged 17 Years and older. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by Hospital Italiano de Buenos Aires · Observational

How we know · 2 judgments

From the registry’s dates

  • Started Jan 2017; still recruiting 9 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
17 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Pulmonary Arterial Hypertension with a site in Argentina — 7 open to participants now, 11 under way, 7 of them phase 3. Pulmonary Arterial Hypertension · Argentina.

Started
2017
with 1 other
Observational
2 of 42
1 open now
Primary completion
2030-12
later than 10 of 10 live
Registered
13th of 42
by date

Among the 42 studies in Pulmonary Arterial Hypertension with a site in Argentina, this one is one of 2 that started in 2017, is one of 2 observational ones, reaches primary completion later than 10 of the 10 other live ones, and was the 13th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

7 of the 42 studies in Pulmonary Arterial Hypertension with a site in Argentina are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 17 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Pulmonary Arterial Hypertension with a site in Argentina, or all of them as a file.
02

Study summary

The purpose of this study is to create a registry of patients with Pulmonary Hypertension who received medical care in the Hospital Italiano of Buenos Aires.

Read the detailed description

The Institutional Registry of Pulmonary Hypertension includes patients prospectively with incident pulmonary hypertension type I. It also includes prevalent cases from our HMO who had diagnosis prior the beginning of the registry.

03

Conditions studied

  • Hypertension, Pulmonary Arterial
04

Who can participate

Ages eligible
17 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who meet inclusion criteria and none of exclusion criteria during the study period are eligible to this study. In the population, the PAH cohort will consist of those incident cases and prevalent cases PAH WHO group 1 aged ≥18 years between January 2017 and December 2030 who attended at Hospital Italiano of Buenos Aires.

Eligibility criteria

  • Inclusion Criteria:

    1. Diagnosed with PAH WHO group 1 (2022 ESC/ESR guidelines criteria) as the presence of a mean pulmonary artery pressure (mPAP) greater than 20 mmHg at rest with pulmonary arterial wedge pressure (PAWP) >15 mmHg and pulmonary vascular resistance (PVR) >2 WU, according to the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
    2. Included in the institutional registry of PAH of Hospital Italiano de Buenos Aires
    3. Aged ≥18 years at the index date.
  • Exclusion Criteria History of lung transplantation surgery previously the baseline period
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Pulmonary Hypertension prevalence

    Pulmonary Hypertension prevalence in our community.

    Time frame: 1 year

  2. Pulmonary Hypertension incidence

    Pulmonary Hypertension incidence in our community

    Time frame: 1 year

Secondary outcomes

  1. Mortality rate

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2017 (actual). Primary completion is estimated for Dec 2030, 167 months after the start.

Of 64 non-industry observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 31. This study's planned 167 months is above that.

Counting every sponsor, half of 85 studies reached it within 58 months; a quarter within 30 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2011
First posted
Dec 29, 2011
StartActual
Jan 1, 2017
Primary completionEst.
Dec 31, 2030
CompletionEst.
Jun 1, 2031
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01501838
Responsible party
Ignacio M Bluro (Principal Investigator, Hospital Italiano de Buenos Aires) — Principal investigator
First posted
Dec 29, 2011
Start date
Jan 1, 2017
Primary completion
Dec 31, 2030 (estimated)
Completion
Jun 1, 2031 (estimated)
Last update
Aug 24, 2025

Study contacts

Ignacio M Bluro, MD
Contact
ignacio.bluro@hospitalitaliano.org.ar
+541149590200 ext. 5303
Ignacio M Bluro, MD
principal investigator · Hospital Italiano de Buenos Aires

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion